Search results

Ron Davis estimated that it would cost about $10 million dollars to do a full blown phase 3 trial. There is a FB group with about 5K members that you could join for more info.

No. IIRC they received cyclophosphamide PLUS ritux. Fluge went with trialing ritux before cyclo. Disabled people going back to work would be good info “to be taken seriously”. See here (trial, not a case study)...

Hi, Any update on this? Thanks

A new frontier: we have treated the first Multiple Sclerosis patient in the US with CAR-T immunotherapy (CD-19) in our Phase 1 Clinical Trial

Lightly peer-reviewed. Submission received: 30 May 2024 / Revised: 1 July 2024 / Accepted: 5 July 2024 / Published: 11 July 2024 Let’s say reviewers had 3 weeks to review. That would mean authors had maybe 5 days to make corrections and resubmit.

A Daughter of Hollywood Royalty Appeals to Los Angeles: No Mask Bans https://www.nytimes.com/2024/07/10/style/violet-affleck-mask-ben-jennifer-garner-daughter.html?unlocked_article_code=1.6U0.XliS.oQgMQq-AKNAn&smid=url-share

Another article here from Stat. https://www.statnews.com/2024/07/10/lupus-research-molecular-switch-possible-new-treatments/

So this is opposite to what Lutter found? Lutter arguing for AHR antagonism whereas Lupus needs an AHR agonist? Interesting...

@Dakota15 Do you know if the USA NGO’s are generally supportive of this $30 million phase 3 study that apparently won’t be completed until 2029? Why isn’t Lilly funding the bulk of this study since this is their patented drug?

At least there is somewhat of a silver lining for Stephen’s illness in that he was able to turn his focus and limited energy into founding this organization that seems to be doing good.

You’ll have to read the article to understand why I posted this here (at least the first paragraph). If you are on Twitter, then you know this person...